These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 33896272)
1. Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition. Lai LP; Brel V; Sharma K; Frappier J; Le-Henanf N; Vivet B; Muzet N; Schell E; Morales R; Rooney E; Basse N; Yi M; Lacroix F; Holderfield M; Englaro W; Marcireau C; Debussche L; Nissley DV; McCormick F SLAS Discov; 2021 Aug; 26(7):922-932. PubMed ID: 33896272 [TBL] [Abstract][Full Text] [Related]
2. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Blake DR; Vaseva AV; Hodge RG; Kline MP; Gilbert TSK; Tyagi V; Huang D; Whiten GC; Larson JE; Wang X; Pearce KH; Herring LE; Graves LM; Frye SV; Emanuele MJ; Cox AD; Der CJ Sci Signal; 2019 Jul; 12(590):. PubMed ID: 31311847 [TBL] [Abstract][Full Text] [Related]
3. CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. Costa-Cabral S; Brough R; Konde A; Aarts M; Campbell J; Marinari E; Riffell J; Bardelli A; Torrance C; Lord CJ; Ashworth A PLoS One; 2016; 11(2):e0149099. PubMed ID: 26881434 [TBL] [Abstract][Full Text] [Related]
4. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158 [TBL] [Abstract][Full Text] [Related]
5. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells. Komatsu N; Fujita Y; Matsuda M; Aoki K Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330 [TBL] [Abstract][Full Text] [Related]
6. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. Guhan SM; Shaughnessy M; Rajadurai A; Taylor M; Kumar R; Ji Z; Rashid S; Flaherty K; Tsao H J Invest Dermatol; 2021 Aug; 141(8):2018-2027.e4. PubMed ID: 33745909 [TBL] [Abstract][Full Text] [Related]
7. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798 [TBL] [Abstract][Full Text] [Related]
8. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468 [TBL] [Abstract][Full Text] [Related]
9. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma. Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099 [TBL] [Abstract][Full Text] [Related]
10. MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. McNew KL; Whipple WJ; Mehta AK; Grant TJ; Ray L; Kenny C; Singh A Mol Cancer Res; 2016 Dec; 14(12):1204-1216. PubMed ID: 27655129 [TBL] [Abstract][Full Text] [Related]
11. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling. Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519 [TBL] [Abstract][Full Text] [Related]
12. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306 [TBL] [Abstract][Full Text] [Related]
13. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer. Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486 [TBL] [Abstract][Full Text] [Related]
14. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764 [TBL] [Abstract][Full Text] [Related]
15. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation. Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243 [TBL] [Abstract][Full Text] [Related]
16. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143 [TBL] [Abstract][Full Text] [Related]
17. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997 [TBL] [Abstract][Full Text] [Related]
18. Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. Haagensen EJ; Thomas HD; Mudd C; Tsonou E; Wiggins CM; Maxwell RJ; Moore JD; Newell DR Eur J Cancer; 2016 Mar; 56():69-76. PubMed ID: 26820797 [TBL] [Abstract][Full Text] [Related]
19. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant? Nussinov R; Tsai CJ; Jang H Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569 [TBL] [Abstract][Full Text] [Related]